What are the side effects of Bosutinib?

Bosutinib, trade nameBosulif, is a small moleculeBCR-ABL and srcTyrosine kinase inhibitor, bosutinib was first approved by the FDA in 2012 for the treatment of chronic, accelerated or blast phase Ph+ in adults who are resistant or intolerant to previous treatments. Chronic myeloid leukemia (CML). 2023Year9Monday26Bosutinib also obtained FDAApproved for the treatment of children with newly diagnosed or /intolerance to CML.

The adverse reactions of bosutinib ≥20% include diarrhea, rash, nausea, abdominal pain, vomiting, fatigue, abnormal liver function, respiratory infection, fever, and headache. Laboratory abnormality reporting rate≥20%:Increased chromium concentration, decreased hemoglobin concentration, decreased lymphocyte count, decreased white blood cell count, decreased absolute neutrophil count, decreased platelet count, aminotransferase concentration(ALT, AST) Elevated, alkaline phosphatase concentration increased, calcium concentration decreased, phosphorus concentration decreased, glucose concentration increased, uric acid concentration increased, lipase concentration increased, creatine kinase(CK, creatine phosphokinase, CPK)concentration increased, amylase concentration increased.

Bosutinib protein binding is 94% in vitro and 96% in vitro and is independent of concentration. Bosutinib is primarily metabolized by CYP3A4. The major circulating metabolites found in plasma are oxydechlorination (M2) and bosutinib (19% of maternal exposure) and N-demethylation (M5)Bosutinib(Maternally exposed25%), BosutinibN-Oxide(M6)are minor circulating metabolites. All metabolites are considered inactive. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.

xa0